Study of CP-COV03 Treatment for Dengue and Dengue-like Illness
Part of Infections clinical trials.
This trial tests whether a new medicine called CP-COV03 can help people recover faster from dengue fever or dengue-like illness. You would receive either the study medicine or a placebo (inactive pill) and be monitored closely to see if symptoms improve.
Summary written for real people, not researchers, by Clin2.
Who can take part
- At least 18 years old
- Fever that started within the last 3 days (72 hours)
- At least 2 dengue symptoms that are moderate to severe (for example: headache, body aches, rash, nausea)
- Confirmed dengue diagnosis by a blood test (NS1 test) or suspected dengue/similar illness
- No previous dengue vaccine
- No severe dengue complications or severe existing health conditions like uncontrolled diabetes or severe asthma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new medicines for people hospitalized with moderate-to-severe dengue fever. Dengue is a mosquito-borne virus that can cause serious complications like severe bleeding, organ damage, or shock. The trial aims to find treatments that help patients recover faster and avoid life-threatening complications.
This trial tests different experimental drugs to treat dengue early. It aims to find which treatment works best and is safe for patients who start within 48 hours of fever.
This trial tests how the dengue virus affects healthy adults who have never been exposed to dengue or similar viruses. You would be given a controlled dose of the virus and closely monitored to help researchers understand the infection and develop better treatments or vaccines.
This trial tests a new experimental drug, EYU688, for adults with dengue fever. It aims to see if the drug is safe and effective. You may qualify if you have early dengue symptoms, have tested positive for dengue, and are otherwise healthy.
This study tests a controlled dengue infection in people who already have immunity to some types of dengue. It aims to understand how the immune system responds and to help develop better vaccines. You may qualify if you are a healthy adult aged 18-40 and have evidence of prior dengue exposure to certain virus types.
This trial tests a new dengue vaccine in adults aged 40 to 79 to see if it can protect them from dengue fever. If you are generally healthy and willing to follow the study schedule, you may be able to join.
Hear when a new Dengue trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.